A recent study found that measuring circulating tumor cells (CTCs) is a reliable way to predict later treatment response and survival prospects in men when…
Category: Research
A team of researchers at the University of Southern California has used a commercial blood test to count circulating tumor cells (CTCs) and predict how…
A blood test that measures the number of circulating tumor cells (CTCs) at the time of metastatic prostate cancer diagnosis can predict treatment response, disease…
In metastatic hormone-sensitive prostate cancer (mHSPC), new first-line combination therapies have enhanced overall survival (OS), but clinical outcomes for individual patients vary greatly and are…
October 07, 2024 “Prostate cancer is the most common malignancy [among] American men and the second most lethal,” Amir Goldkorn, MD, professor of medicine and biochemistry & molecular…
The non-invasive test, which measures circulating tumor cells in the blood, can predict treatment response, disease progression and overall survival in men newly diagnosed with…
SWOG’s ASCO 2023 preview highlights Goldkorn Lab liquid biopsy research in two abstracts
Posted in Conference, Research, and SWOG studies
SWOG Presents 30 Abstracts at ASCO 2023 | SWOG “Here are highlights from some of the other SWOG work to be presented at ASCO 2023…
The February issue of National Geographic magazine featured an article providing readers with a broad overview of what liquid biopsies are and what they have…
Goldkorn Lab presents research into cell-free DNA methylation at ASCO 2022
Posted in Conference, Research, and Video
The ASCO 2022 annual meeting was held last month, and on June 3rd, the Goldkorn Lab presented an oral abstract showcasing research done in cooperation…
Amir joins Dr. Tom Powles and Dr. Brian Rini on the Kidney Cancer Association’s Uromigos podcast to discuss the results of the S1314 clinical trial,…